(1) The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA;(2) The Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
Abstract:
Purpose
An open-label Phase 1 study of recombinant prime-boost poxviruses targeting CEA and MUC-1 in patients with advanced pancreatic
cancer was conducted to determine safety, tolerability and obtain preliminary data on immune response and survival.